Terms: = Leukemia AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
38 results:
1. Non-IG::myc in diffuse large B-cell lymphoma confers variable genomic configurations and myc transactivation potential.
Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
[TBL] [Abstract] [Full Text] [Related]
2. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
3. RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H; Ueno H; Tasaka K; Isobe T; Saida S; Kato I; Umeda K; Hiwatari M; Hasegawa D; Imamura T; Kakiuchi N; Nannya Y; Ogawa S; Hiramatsu H; Takita J
Blood Adv; 2024 Mar; 8(5):1258-1271. PubMed ID: 38127276
[TBL] [Abstract] [Full Text] [Related]
4. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.
Kumar A; Taghi Khani A; Duault C; Aramburo S; Sanchez Ortiz A; Lee SJ; Chan A; McDonald T; Huang M; Lacayo NJ; Sakamoto KM; Yu J; Hurtz C; Carroll M; Tasian SK; Ghoda L; Marcucci G; Gu Z; Rosen ST; Armenian S; Izraeli S; Chen CW; Caligiuri MA; Forman SJ; Maecker HT; Swaminathan S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217248
[TBL] [Abstract] [Full Text] [Related]
5. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer.
Ortiz-Barahona V; Soler M; Davalos V; García-Prieto CA; Janin M; Setien F; Fernández-Rebollo I; Bech-Serra JJ; De La Torre C; Guil S; Villanueva A; Zhang PH; Yang L; Guarnacci M; Schumann U; Preiss T; Balaseviciute U; Montal R; Llovet JM; Esteller M
Mol Cancer; 2023 May; 22(1):83. PubMed ID: 37173708
[TBL] [Abstract] [Full Text] [Related]
6. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-myc rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
7. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
[TBL] [Abstract] [Full Text] [Related]
8. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and myc downregulation.
Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
[TBL] [Abstract] [Full Text] [Related]
9. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
10. CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
[TBL] [Abstract] [Full Text] [Related]
11. Is acute lymphoblastic leukemia with mature B-cell phenotype and
Hidalgo-Gómez G; Palacio-Garcia C; Gallur L; Blanco A; Tazón-Vega B; Saumell S; Martínez N; Murillo L; Murciano T; Velasco P; Bosch F; Diaz-Heredia C; Ortega M
Leuk Lymphoma; 2021 Sep; 62(9):2202-2210. PubMed ID: 33827367
[TBL] [Abstract] [Full Text] [Related]
12. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract] [Full Text] [Related]
13. Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patients' prognosis.
Cardona-Echeverry A; Prada-Arismendy J
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3097-3109. PubMed ID: 32980885
[TBL] [Abstract] [Full Text] [Related]
14. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
15. myc copy number and mRNA expression in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chornobyl NPP accident.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2020 Mar; 42(1):60-65. PubMed ID: 32231192
[TBL] [Abstract] [Full Text] [Related]
16. Novel synthetic tosyl chloride-berbamine regresses lethal myc-positive leukemia by targeting CaMKIIγ/myc axis.
Yu Q; Wang P; Yang L; Wu Z; Li S; Xu Y; Wu B; Ma A; Gan X; Xu R
Biomed Pharmacother; 2019 Sep; 117():109134. PubMed ID: 31247466
[TBL] [Abstract] [Full Text] [Related]
17. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Saenz DT; Fiskus W; Manshouri T; Mill CP; Qian Y; Raina K; Rajapakshe K; Coarfa C; Soldi R; Bose P; Borthakur G; Kadia TM; Khoury JD; Masarova L; Nowak AJ; Sun B; Saenz DN; Kornblau SM; Horrigan S; Sharma S; Qiu P; Crews CM; Verstovsek S; Bhalla KN
Leukemia; 2019 Jun; 33(6):1373-1386. PubMed ID: 30575820
[TBL] [Abstract] [Full Text] [Related]
18. Senescence-associated reprogramming promotes cancer stemness.
Milanovic M; Fan DNY; Belenki D; Däbritz JHM; Zhao Z; Yu Y; Dörr JR; Dimitrova L; Lenze D; Monteiro Barbosa IA; Mendoza-Parra MA; Kanashova T; Metzner M; Pardon K; Reimann M; Trumpp A; Dörken B; Zuber J; Gronemeyer H; Hummel M; Dittmar G; Lee S; Schmitt CA
Nature; 2018 Jan; 553(7686):96-100. PubMed ID: 29258294
[TBL] [Abstract] [Full Text] [Related]
19. Mutations driving CLL and their evolution in progression and relapse.
Landau DA; Tausch E; Taylor-Weiner AN; Stewart C; Reiter JG; Bahlo J; Kluth S; Bozic I; Lawrence M; Böttcher S; Carter SL; Cibulskis K; Mertens D; Sougnez CL; Rosenberg M; Hess JM; Edelmann J; Kless S; Kneba M; Ritgen M; Fink A; Fischer K; Gabriel S; Lander ES; Nowak MA; Döhner H; Hallek M; Neuberg D; Getz G; Stilgenbauer S; Wu CJ
Nature; 2015 Oct; 526(7574):525-30. PubMed ID: 26466571
[TBL] [Abstract] [Full Text] [Related]
20. Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma.
Xi Y; Li J; Zhang P; Bai W; Gao N; Bai W; Zhang Y; Wu Y; Ning Y
Exp Mol Pathol; 2015 Oct; 99(2):297-302. PubMed ID: 26231295
[TBL] [Abstract] [Full Text] [Related]
[Next]
